Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6124125 | 0.87 | HRH1 (0.42) | HRH1DPP8DPP9HRH3GRIN2D | |
| SCHEMBL29391878 | 0.87 | HRH1 (0.42) | HRH1DPP8DPP9HRH3GRIN2D | |
| SCHEMBL9963375 | 0.84 | DPP8 (0.46) | HRH1DPP8DPP9HRH3ADORA2A | |
| SCHEMBL20170864 | 0.82 | ADORA2A (0.42) | HRH1DPP8DPP9ADORA2AGRIN2D | |
| SCHEMBL24487991 | 0.79 | MEN1 (0.42) | HRH1DPP8DPP9HRH3ADORA2A | |
| SCHEMBL20132711 | 0.79 | MEN1 (0.42) | HRH1DPP8DPP9HRH3ADORA2A | |
| SCHEMBL8475722 | 0.77 | MAOA (0.57) | HRH1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29391241 | 0.77 | MAOA (0.57) | HRH1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13937968 | 0.77 | CHRNA7 (0.35) | HRH1HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL19164017 | 0.77 | HRH3 (0.33) | HRH3KCNH2KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2023247595-A1 | PYRAZOLOPYRAZINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023107606-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20100305090-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100029634-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100016289-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20100016289-A1 | Compounds Useful as Antagonists of CCR2 | MILLENNIUM PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| WO-2009121063-A2 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2009-10-01 | — | — | WO | disclosed |
| US-7482336-B2 | Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20070254865-A1 | 2-substituted phenyl-5-fused heteroaryl cyclohexylamines; may be coadministered with metformin; non-insulin dependent diabetes | MERCK SHARP & DOHME LLC | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016289-A1 | Compounds Useful as Antagonists of CCR2 | CCR2, CCR1, CXCR3 | HRH1 201/4885DPP8 2121/4885DPP9 1968/4885 |
| US-20100305090-A1 | META-SUBSTITUTED PHENYL SULFONYL AMIDES OF SECONDARY AMINO ACID AMIDES, THE PRODUCTION THEREOF, AND USE THEREOF AS MATRIPTASE INHIBITORS | MMP7, DNPEP, METAP1 | HRH1 2266/4885DPP8 25/4885DPP9 9/4885 |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | HRH1 3317/4885DPP8 2998/4885DPP9 1352/4885 |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | MSH2, PMS2, MSH6 | HRH1 704/4885DPP8 3848/4885DPP9 3437/4885 |
| US-20070254865-A1 | 2-substituted phenyl-5-fused heteroaryl cyclohexylamines; may be coadministered with metformin; non-insulin dependent diabetes | DPP4, DPP3, DPP7 | HRH1 2458/4885DPP8 4/4885DPP9 5/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | HRH1 2294/4885DPP8 798/4885DPP9 731/4885 |
| US-20100029634-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | HRH1 1455/4885DPP8 2378/4885DPP9 2039/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | HRH1 3069/4885DPP8 2976/4885DPP9 1231/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | HRH1 3267/4885DPP8 2648/4885DPP9 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.